《Investigational New Drugs》雜志的最新年發文量為87篇。
這表明該刊在每年都會精選并發表一定數量的高質量文章，以保持其在藥學領域的學術影響力。
該刊聚焦于醫學-藥學領域的前沿研究，致力于推動該領域新技術和新知識的傳播與應用。同時它積極鼓勵研究人員詳細發表其高質量的實驗研究和理論成果。
該刊的平均審稿周期約為 約1.0個月 。
Investigational New Drugs 雜志發文統計
文章名稱引用次數
- Incidence of immune-related adverse events and its association with treatment outcomes: the MD Anderson Cancer Center experience28
- Clinical toxicity of antibody drug conjugates: a meta-analysis of payloads28
- Phase Ib/II study of gemcitabine, nab-paclitaxel, and pembrolizumab in metastatic pancreatic adenocarcinoma23
- Nab-paclitaxel plus gemcitabine versus FOLFIRINOX as the first-line chemotherapy for patients with metastatic pancreatic cancer: retrospective analysis22
- Radiomics to predict immunotherapy-induced pneumonitis: proof of concept19
- Safety, pharmacokinetic, and pharmacodynamics of erdafitinib, a pan-fibroblast growth factor receptor (FGFR) tyrosine kinase inhibitor, in patients with advanced or refractory solid tumors18
- Emerging roles of non-coding RNAs in the pathogenesis, diagnosis and prognosis of osteosarcoma18
- Characteristics of patients with sorafenib-treated advanced hepatocellular carcinoma eligible for second-line treatment15
- Multicenter retrospective analysis of the safety and efficacy of regorafenib after progression on sorafenib in Korean patients with hepatocellular carcinoma14
- Lopinavir-NO, a nitric oxide-releasing HIV protease inhibitor, suppresses the growth of melanoma cells in vitro and in vivo13
國家/地區發文量
- USA170
- CHINA MAINLAND113
- Japan101
- France30
- Canada29
- GERMANY (FED REP GER)27
- South Korea27
- Italy25
- Spain20
- Brazil19
